FOXD1 and nasopharyngeal carcinoma: In future work, validating NAT10/FOXD1 co-expression in large-scale NPC cohorts and exploring synergistic therapies combining NAT10 inhibitors with anti-angiogenic agents or immunotherapies are warranted.